Figure 15From: Comparison of the efficacy of lamivudine and telbivudine in the treatment of chronic hepatitis B: a systematic reviewEnd of one-years and two-years in HBsAg response, viral breakthrough, viral resistance, adverse events and creatine kinase.Back to article page